NCT05223166已完成3 期
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea
Citrine Medicine Limited1 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2022年4月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- Change from baseline of ESS
研究概览
简要总结
The objective of this study is to demonstrate the efficacy and safety of pitolisant versus placebo during 12 weeks of the Double Blind period, to treat the Excessive Daytime Sleepiness (EDS) in patients with Obstructive Sleep Apnea (OSA) not tolerating or refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapy or treated by nCPAP but still complaining of EDS.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion criteria
- •Voluntarily participate in the clinical study; fully understand and know the study and sign the informed consent form (ICF); willing to follow and able to complete all study procedures;
- •Male or female aged 18 years to 70 years;
- •Subjects affected by Obstructive Sleep Apnoea (OSA) with excessive daytime sleepiness;
- •Female subjects of childbearing potential must have a negative serum pregnancy test 1 week before the first dose; female subjects or male subjects with a spouse of childbearing potential must agree to take contraceptive measures from the signing of the informed consent form to 1 months after the last dose of study drug;
- •Subjects must be willing not to operate a car (if sleepy at wheel) or heavy machinery for the duration of the study or as long as the investigator deems it clinically indicated. In addition, subjects need to be willing to maintain daily behaviors (e.g., circadian rhythm, caffeine intake, nocturnal sleep duration, etc.) during the study that may affect their daytime sleepiness.
排除标准
- •Participated in any other drug clinical trial or receiving other clinical trial treatment within 30 days before the first dose;
- •Subjects who have previously received pitolisant, either from other clinical studies of pitolisant or from the subject use program, or from treatment with commercially available pitolisant (Wakix ®);
- •Use of prohibited drugs specified in the protocol within 14 days before enrollment;
- •The mean oxygen saturation < 85% or the lowest oxygen saturation < 70% by PSG.
- •Acute or chronic diseases affecting efficacy evaluation, such as severe chronic obstructive pulmonary disease (COPD);
- •Previous history of drug, alcohol, narcotic or other drug abuse or dependence;
- •Any serious cardiovascular system abnormalities (e.g., ischemic cardio-cerebral disease), such as recent myocardial infarction, angina, severe hypertension or arrhythmia in the recent 6 months, ECG Fridericia-corrected QT interval higher than 450 ms, history of left ventricular hypertrophy or mitral valve prolapse;
- •Subjects with severe co-morbid medical or biological conditions that may jeopardize participation in the study (especially cardiovascular system problems and unstable diabetes) as judged by the investigator;
- •Any positive serology test for HIV, HCV, HBsAg and syphilis;
- •Female subjects who are pregnant or breast-feeding;
- •Known or suspected hypersensitivity to study drug or to any excipients;
- •Cognitive impairment due to any psychiatric or neurological condition, including epilepsy and dementia, which may limit the understanding, execution of the informed consent form, and compliance of the study;
- •Presence of severe hepatic insufficiency (Child Pugh C) or severe renal impairment (eGFR<30 ml/min/1.73㎡), or other significant abnormalities in physical examination/clinical laboratory tests, and any clinically significant condition that may interfere with the subject's completion of the study;
- •Subjects who are judged by the investigator to be unsuitable for this study.
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo
干预措施: Placebo oral tablet (Drug)
Pitolisant
Experimental
Histamine H3 receptor H3R antagonist/ inverse agonist
干预措施: Pitolisant (Drug)
结局指标
主要结局
Change from baseline of ESS
时间窗: 12 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label ExtensionPrader-Willi SyndromeNCT04257929Harmony Biosciences Management, Inc.65
已完成
2 期
Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1Myotonic Dystrophy 1Excessive Daytime SleepinessNCT04886518Harmony Biosciences Management, Inc.30
已完成
3 期
A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic HypersomniaIdiopathic HypersomniaNCT05156047Harmony Biosciences, LLC214
已完成
3 期
Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label PeriodNarcolepsy With CataplexyNarcolepsy Without CataplexyNCT02611687Bioprojet110
已完成
2 期
A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction ProcedureSedationPainAnxietyNCT00894699Talphera, Inc40